The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D.

Arda-Pirincci P, Bolkent S

Molecular and cellular biochemistry14 Dec 2010Cited by 35 (Europe PMC)

PMID21153865DOI10.1007/s11010-010-0678-0PepBankPUB-21153865

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment significantly reduced intestinal injury versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment reduced intestinal injury versus injury without pretreatment.
Peptide
Teduglutide
Outcome
DecreaseIntestinal injury
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
h[Gly(2)]GLP-2 pretreatment prevented the TNF-α/Act D-induced oxidative injury by a significant reduction in the intestinal injury, apoptotic index, expression of active caspase-3, lipid peroxidation and GSH levels, GPx and SOD activities;
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386501
02AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment significantly reduced apoptotic index versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment reduced cell death versus injury without pretreatment.
Peptide
Teduglutide
Outcome
DecreaseApoptotic index
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Cell viability and death · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
h[Gly(2)]GLP-2 pretreatment prevented the TNF-α/Act D-induced oxidative injury by a significant reduction in the intestinal injury, apoptotic index, expression of active caspase-3, lipid peroxidation and GSH levels, GPx and SOD activities;
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386502
03AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment significantly reduced active caspase-3 expression versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment reduced active caspase-3 expression versus injury without pretreatment.
Peptide
Teduglutide
Outcome
DecreaseActive caspase-3 expression
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Cell viability and death · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
h[Gly(2)]GLP-2 pretreatment prevented the TNF-α/Act D-induced oxidative injury by a significant reduction in the intestinal injury, apoptotic index, expression of active caspase-3, lipid peroxidation and GSH levels, GPx and SOD activities;
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386503
04AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment significantly reduced lipid peroxidation versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment reduced lipid oxidation versus injury without pretreatment.
Peptide
Teduglutide
Outcome
DecreaseLipid peroxidation
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Oxidative stress · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
h[Gly(2)]GLP-2 pretreatment prevented the TNF-α/Act D-induced oxidative injury by a significant reduction in the intestinal injury, apoptotic index, expression of active caspase-3, lipid peroxidation and GSH levels, GPx and SOD activities;
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386504
05AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment significantly reduced GSH levels versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment reduced glutathione levels versus injury without pretreatment.
Peptide
Teduglutide
Outcome
DecreaseGlutathione levels
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Oxidative stress · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
h[Gly(2)]GLP-2 pretreatment prevented the TNF-α/Act D-induced oxidative injury by a significant reduction in the intestinal injury, apoptotic index, expression of active caspase-3, lipid peroxidation and GSH levels, GPx and SOD activities;
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386505
06AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment significantly reduced GPx activity versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment reduced glutathione peroxidase activity versus injury without pretreatment.
Peptide
Teduglutide
Outcome
DecreaseGlutathione peroxidase activity
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Oxidative stress · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
h[Gly(2)]GLP-2 pretreatment prevented the TNF-α/Act D-induced oxidative injury by a significant reduction in the intestinal injury, apoptotic index, expression of active caspase-3, lipid peroxidation and GSH levels, GPx and SOD activities;
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386506
07AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment significantly reduced SOD activity versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment reduced superoxide dismutase activity versus injury without pretreatment.
Peptide
Teduglutide
Outcome
DecreaseSuperoxide dismutase activity
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Oxidative stress · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
h[Gly(2)]GLP-2 pretreatment prevented the TNF-α/Act D-induced oxidative injury by a significant reduction in the intestinal injury, apoptotic index, expression of active caspase-3, lipid peroxidation and GSH levels, GPx and SOD activities;
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386507
08AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment markedly increased cell proliferation versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment increased cell proliferation versus injury without pretreatment.
Peptide
Teduglutide
Outcome
IncreaseCell proliferation
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
a markedly increase in cell proliferation, and CAT activity.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386508
09AnimalAnimal study (in vivo)Efficacy outcome
In mice, teduglutide pretreatment markedly increased CAT activity versus TNF-α/Act D injury without pretreatment.
In plain wordsIn mice, teduglutide pretreatment increased catalase activity versus injury without pretreatment.
Peptide
Teduglutide
Outcome
IncreaseCatalase activity
Study
mousen: not reported in source
TNF-α/Act D intestinal injury
Comparator
TNF-α/Act D without pretreatment
Outcome group
Oxidative stress · Gastrointestinal
Studied dose
200 μg/kg every 12 h · subcutaneous · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
a markedly increase in cell proliferation, and CAT activity.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we evaluated this potential of GLP-2 on apoptosis, cell proliferation, and oxidant-antioxidant system on a mouse model of intestinal injury induced by TNF-α/Act D.
Summary · context
Animals were injected subcutaneously 200 μg/kg h[Gly(2)]GLP-2 every 12 h for 10 consecutive days prior to the administration of TNF-α and Act D.
Report a problemFND-2115386509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.